Suppr超能文献

从人内皮细胞中分离出一种新型45 kDa纤溶酶原受体。

Isolation of a novel 45 kDa plasminogen receptor from human endothelial cells.

作者信息

Dudani A K, Cummings C, Hashemi S, Ganz P R

机构信息

Department of Medicine, University of Ottawa, Ontario, Canada.

出版信息

Thromb Res. 1993 Jan 15;69(2):185-96. doi: 10.1016/0049-3848(93)90044-o.

Abstract

We have previously identified an endothelial cell membrane protein of M(r) 45 kDa that binds plasminogen in a kringle-dependent, specific and reversible manner (Dudani et. al. (1991) Mol. Cell. Biochem. 108: 133-139). In this study, we have developed and optimized a protocol for the isolation of the 45 kDa plasminogen receptor from venous endothelial cells using a four step procedure consisting of lysis and detergent extraction followed by ligand affinity chromatography and preparative polyacrylamide gel electrophoresis. Control experiments were carried out using BSA-Sepharose instead of plasminogen-Sepharose as the affinity matrix. No plasminogen binding proteins were recovered from the former columns. However, a 45 kDa protein was recovered from lysine eluates of plasminogen-Sepharose. This material was then purified to homogeneity using preoperative electrophoresis. Analyses of proteins at various steps in the purification by SDS-PAGE showed enrichment of a band of 45 kDa which superimposed with the observed binding activity of plasminogen in ligand blots. The above binding could be inhibited by excess lysine. The 45 kDa protein could be distinguished from alpha-enolase which also binds plasminogen by: (i) significant differences in the profile of retention times of CNBr-degradation fragments on reversed phase HPLC; and (ii) partial peptide sequencing of one of the CNBr-degradation fragments of the 45 kDa protein. Moreover, the derived sequence did not show any significant homology to any protein in the Swiss Prot (release 20) database. We thus propose that the 45 kDa protein represents a novel plasminogen receptor on human venous endothelial cells.

摘要

我们之前鉴定出一种分子量为45 kDa的内皮细胞膜蛋白,它能以一种依赖kringle结构域、特异性且可逆的方式结合纤溶酶原(Dudani等人,(1991)《分子与细胞生物化学》108: 133 - 139)。在本研究中,我们开发并优化了一种从静脉内皮细胞中分离45 kDa纤溶酶原受体的方案,该方案采用四步程序,包括裂解和去污剂提取,随后进行配体亲和层析和制备性聚丙烯酰胺凝胶电泳。使用牛血清白蛋白琼脂糖(BSA - Sepharose)代替纤溶酶原琼脂糖(plasminogen - Sepharose)作为亲和基质进行对照实验。从前者的柱中未回收纤溶酶原结合蛋白。然而,从纤溶酶原琼脂糖的赖氨酸洗脱液中回收了一种45 kDa的蛋白。然后使用制备前电泳将该物质纯化至同质。通过SDS - PAGE对纯化过程中各个步骤的蛋白质进行分析,结果显示一条45 kDa的条带得到富集,该条带与配体印迹中观察到的纤溶酶原结合活性重叠。上述结合可被过量赖氨酸抑制。该45 kDa蛋白可通过以下方式与也能结合纤溶酶原的α - 烯醇酶区分开来:(i) 反相高效液相色谱(HPLC)上CNBr降解片段保留时间谱的显著差异;以及 (ii) 对45 kDa蛋白的一个CNBr降解片段进行部分肽测序。此外,推导的序列与瑞士蛋白质数据库(Swiss Prot,版本20)中的任何蛋白质均无显著同源性。因此,我们认为该45 kDa蛋白代表了人静脉内皮细胞上一种新的纤溶酶原受体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验